XEN Appointed as Exclusive Biomiq Skincare China Distributor
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Xenitra Limited has announced its appointment as the exclusive distributor for Biomiq Skincare in Greater China under a four-year agreement with Servatus Ltd. The agreement includes a minimum purchase commitment from Xenitra to retain exclusivity, with specific targets set for each year of the contract. Biomiq Skincare offers a range of products aimed at treating acne and other skin conditions, and is noted for its rapid sales growth in Australia. The distribution agreement is part of Xenitra's strategy to integrate brands into its blockchain tokenised sales ecosystem, enhancing market access in Asia.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Xenitra
- Product sales of $500k in first month of OPAL token launch
- $1.25m Raised to Support Next Phase of Growth
- OPAL token launch of EZZ products sells $100k in first week
- Q3 Sales rise by over 305% to $8.3m
- Acquisition of Fukang OTC Pharmacy
Later from Xenitra
- $1.1m in OPAL-Tokenised Product Sales in First 7 Weeks
- $12M offtake agreement with leading OTC-pharmaceutical
- Investor Webinar
- Quarterly Activities/Appendix 4C Cash Flow Report
- Investor Presentation
Follow Xenitra into a list and get an email when it puts out news.
Follow Xenitra